The Joint United Nations Program on HIV and AIDS (UNAIDS) 90-90-90 targets call for 90 percent of all people living with HIV to know their HIV status, 90 percent of all people diagnosed with HIV infection to receive antiretroviral therapy (ART), and 90 percent of those receiving ART to achieve durable viral suppression by the year 2020. In a study appearing in PLOS Medicine, Vincent Habiyambere of the World Health Organization (WHO) and colleagues find that insufficient capacity to perform laboratory tests used in monitoring HIV infection, and underutilization of existing testing capacity, are limiting the ability to meet these goals.
The researchers analyzed responses to annual surveys sent to WHO offices from 127 countries between 2012 and 2014. Respondents each reported on the capacity and usage of CD4 testing, HIV viral load (VL) testing, and early infant diagnosis in their country. The researchers found that the capacity of available CD4 instruments was sufficient to meet the demand of all people living with HIV/AIDS (PLWHA), irrespective of treatment status, but VL capacity was inadequate to cover needs in most reporting countries. Even when capacity was sufficient, machines were being underutilized; only 13.7% of existing CD4 capacity and only 36.5% of existing VL capacity were utilized across reporting countries in 2013.
Habiyambere and colleagues note that the responses were limited to national programs and did not include testing capacity in the private sector, and that incomplete responses or non-response to surveys limit the comprehensiveness of the survey data. However, they note that these findings identify shortfalls in VL testing capacity and underutilization of CD4 and VL technologies that will need to be addressed to reach the UNAIDS targets. They say: "With laboratory systems in reporting countries expanding, a national laboratory strategic plan to strengthen services must be developed, implemented, and monitored by governments and their national and international partners. The focus of international community, to ensure optimal use of laboratory technologies, should be on those countries where interventions for scaling up access to HIV diagnostic technologies are most needed."
In an accompanying Perspective, Peter Kilmarx and Ravia Simbi discuss the practical challenges of achieving high capacity and efficiency in all stages of HIV care and note that moving forward, "strong leadership, resources, planning, and management are needed to scale up laboratory services. Continuing monitoring efforts, like those of Habiyambere and colleagues, are essential."
Reference: Habiyambere V, Ford N, Low-Beer D, Nkengasong J, Sands A, Pérez González M, et al. (2016) Availability and Use of HIV Monitoring and Early Infant Diagnosis Technologies in WHO Member States in 2011-2013: Analysis of Annual Surveys at the Facility Level. PLoS Med 13(8): e1002088. doi:10.1371/journal.pmed.1002088
Source: PLOS
Outbreak Detection, Patient Protection: The Legal Upside of Genomics in Infection Prevention
May 21st 2025A string of infections following routine knee surgeries in Tennessee has escalated into litigation, raising questions about how—and when—health care facilities should detect outbreaks. As genomic surveillance gains traction in infection prevention, some fear it could increase legal risk. In reality, it may offer hospitals their strongest legal defense.
Silent Saboteurs: Managing Endotoxins for Sepsis-Free Sterilization
Invisible yet deadly, endotoxins evade traditional sterilization methods, posing significant risks during routine surgeries. Understanding and addressing their threat is critical for patient safety.